Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An instance of secondary polycythemia that is acquired during the lifetime of the individual.
Biomarker and diagnostic research for acquired secondary polycythemia has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for acquired secondary polycythemia.
12 publications have been identified in PubMed for acquired secondary polycythemia. Research spans Case Report / Case Series (33%), Diagnostic / Biomarker (17%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 4 | 33% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 11:12 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acquired secondary polycythemia
2 |
17% |
Research summaries | 2 | 17% |
Laboratory research | 2 | 17% |
Disease patterns and progression | 1 | 8% |
New treatment approaches | 1 | 8% |
Gendrot B (2026). [PMID: 42120370](https://pubmed.ncbi.nlm.nih.gov/42120370/). *Blood Cancer J*. [Review / Meta-Analysis]
Kuruoğlu T (2026). [PMID: 42043354](https://pubmed.ncbi.nlm.nih.gov/42043354/). *Mikrobiyol Bul*. [Case Report / Case Series]
Cusenza VY (2025). [PMID: 41431006](https://pubmed.ncbi.nlm.nih.gov/41431006/). *Medicine*. [Case Report / Case Series]
Szuber N (2025). [PMID: 40084464](https://pubmed.ncbi.nlm.nih.gov/40084464/). *American journal of hematology*. [Gene Therapy / Novel Therapeutics]
Gangat N (2025). [PMID: 41123216](https://pubmed.ncbi.nlm.nih.gov/41123216/). *American journal of hematology*. [Review / Meta-Analysis]
Tremblay D (2025). [PMID: 39556352](https://pubmed.ncbi.nlm.nih.gov/39556352/). *JAMA*. [Basic Science / Preclinical]
Martin L (2025). [PMID: 40305710](https://pubmed.ncbi.nlm.nih.gov/40305710/). *The New England journal of medicine*. [Epidemiology / Natural History]
Alkhaldy HY (2024). [PMID: 38868887](https://pubmed.ncbi.nlm.nih.gov/38868887/). *Clinical laboratory*. [Diagnostic / Biomarker]
Alsayed A (2024). [PMID: 39421127](https://pubmed.ncbi.nlm.nih.gov/39421127/). *Cureus*. [Case Report / Case Series]
Anžej Doma S (2024). [PMID: 39309680](https://pubmed.ncbi.nlm.nih.gov/39309680/). *Frontiers in medicine*. [Case Report / Case Series]